HeartCare-B (06609.HK) Surges Nearly 7% in Late Trading as H1 Profitability Achieved and R&D-Manufacturing-Sales Integration Strengthens

According to the Zhongtong Finance APP, HeartCare-B (06609) rose nearly 7% in the afternoon trading. As of press time, it increased by 6.8%, reaching HKD 64.4, with a turnover of HKD 25.0596 million.

In terms of news, HeartCare recently announced its interim performance. In the first half of the year, the company's revenue reached 186 million yuan, a year-on-year increase of 44.4%; the net profit attributable to shareholders was 50.9 million yuan, achieving a turnaround from loss to profit year-on-year, and has successfully crossed the break-even point. (Source: Zhitong Securities APP)"New Product Launch and R&D-Production-Sales Integration Closed Loop Established, HeartCare (06609) Experiences 'Davis Double Play'"It was pointed out that, with the quantified contribution of hemorrhagic products in the first half of the year and the continuous iteration of the ischemic product portfolio, the ongoing refinement of the "surgical closed-loop" for access/ hemostasis became the main driver of HeartCare's revenue growth in the first half of the year.

Moreover, while accelerating "open source and cost reduction," in recent years, HeartCare has been further perfecting its integrated innovation loop of research, production, and sales, strengthening the foundation for the company's leap from "structural groundwork" to "commercial realization." To date, the company has received NMPA approval for 32 medical device products, FDA approval for three devices, and a CE mark for one product. The product pipeline broadly covers treatments for acute ischemic stroke and neurovascular stenosis, prevention of ischemic stroke, treatment of hemorrhagic stroke, as well as interventional access.